This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Teicher, B. A. Search for Related Content PubMed PubMed Citation Articles by Teicher, B. A.

Transforming Growth Factor-ß and the Immune Response to Malignant Disease

Author's Affiliation: Genzyme Corporation, Framingham, Massachusetts

Requests for reprints: Beverly A. Teicher, Genzyme Corporation, 5 Mountain Road, Framingham, MA 01701-9322. Phone: 508-271-2843; Fax: 508-620-1203; E-mail: Beverly.Teicher{at}Genzyme.com.

Abstract

Transforming growth factor-ß (TGF-ß) is a key player in malignant disease through its actions on host tissues and cells. Malignant cells often secrete large amounts of TGF-ß that act on nontransformed cells present in the tumor mass as well as distal cells in the host to suppress antitumor immune responses creating an environment of immune tolerance, augmenting angiogenesis, invasion and metastasis, and increasing tumor extracellular matrix deposition. Cells of the innate immune system contribute to the high concentrations of TGF-ß found in tumor masses. In addition, dendritic cell subpopulations secreting TGF-ß contribute to the generation of regulatory T cells that actively inhibit the activity of other T cells. Elevated levels of plasma TGF-ß are associated with advanced stage disease and may separate patients into prognostically high-risk populations. Anti–TGF-ß therapy could reverse the immunosuppressive effects of this cytokine on the host as well as decrease extracellular matrix formation, decrease angiogenesis, decrease osteolytic activity, and increase the sensitivity of the malignant cells to cytotoxic therapies and immunotherapies. Phase I clinical trials of an inhibitor of TGF-ß receptor type I kinase activity and a TGF-ß neutralizing antibody are under way.

This article has been cited by other articles:

				O. J. Finn Cancer Immunology N. Engl. J. Med., June 19, 2008; 358(25): 2704 - 2715. [Full Text] [PDF]

				A. Wallace, V. Kapoor, J. Sun, P. Mrass, W. Weninger, D. F. Heitjan, C. June, L. R. Kaiser, L. E. Ling, and S. M. Albelda Transforming Growth Factor-{beta} Receptor Blockade Augments the Effectiveness of Adoptive T-Cell Therapy of Established Solid Cancers Clin. Cancer Res., June 15, 2008; 14(12): 3966 - 3974. [Abstract] [Full Text] [PDF]

				J.-S. Nam, M. Terabe, M. Mamura, M.-J. Kang, H. Chae, C. Stuelten, E. Kohn, B. Tang, H. Sabzevari, M. R. Anver, et al. An Anti-Transforming Growth Factor {beta} Antibody Suppresses Metastasis via Cooperative Effects on Multiple Cell Compartments Cancer Res., May 15, 2008; 68(10): 3835 - 3843. [Abstract] [Full Text] [PDF]